Relaxin

• 

  Subject Areas on Research

  • A multimarker multi-time point-based risk stratification strategy in acute heart failure: results from the RELAX-AHF trial. 
  • Acute decompensated heart failure: update on new and emerging evidence and directions for future research. 
  • Advancing care for acute heart failure--no time to relax. 
  • Anterior cruciate ligament injuries in the female athlete. 
  • Day vs night: Does time of presentation matter in acute heart failure? A secondary analysis from the RELAX-AHF trial. 
  • Design of the RELAXin in acute heart failure study. 
  • Early drop in systolic blood pressure and worsening renal function in acute heart failure: renal results of Pre-RELAX-AHF. 
  • Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. 
  • Effect of serelaxin on mode of death in acute heart failure: results from the RELAX-AHF study. 
  • Effects of Serelaxin in Patients with Acute Heart Failure. 
  • Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF. 
  • Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF. 
  • Effects of serelaxin on the outcome of patients with or without substantial peripheral edema: A subgroup analysis from the RELAX-AHF trial. 
  • Granulosa cell differentiation in vitro: effect of insulin on growth and functional integrity. 
  • Growth differentiation factor 15 (GDF-15) in patients admitted for acute heart failure: results from the RELAX-AHF study. 
  • Liver function, in-hospital, and post-discharge clinical outcome in patients with acute heart failure-results from the relaxin for the treatment of patients with acute heart failure study. 
  • Low lymphocyte ratio as a novel prognostic factor in acute heart failure: results from the Pre-RELAX-AHF study. 
  • Matching mechanism of death with mechanism of action: considerations for drug development for hospitalized heart failure. 
  • Not time to RELAX in acute heart failure. 
  • Permutation criteria to evaluate multiple clinical endpoints in a proof-of-concept study: lessons from Pre-RELAX-AHF. 
  • Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. 
  • Relaxin suppresses atrial fibrillation by reversing fibrosis and myocyte hypertrophy and increasing conduction velocity and sodium current in spontaneously hypertensive rat hearts. 
  • Relaxin suppresses atrial fibrillation in aged rats by reversing fibrosis and upregulating Na+ channels. 
  • Relaxin treatment of solid tumors: effects on electric field-mediated gene delivery. 
  • Relaxin, a pleiotropic vasodilator for the treatment of heart failure. 
  • Relaxin-2 and Soluble Flt1 Levels in Peripartum Cardiomyopathy: Results of the Multicenter IPAC Study. 
  • Reply: Mode of Death Prevention by Serelaxin. 
  • Reply: considerations for drug development for heart failure. 
  • Representativeness of RELAX-AHF clinical trial population in acute heart failure. 
  • Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial. 
  • Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial. 
  • Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study. 
  • Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. 
  • Serial high sensitivity cardiac troponin T measurement in acute heart failure: insights from the RELAX-AHF study. 
  • Sex differences in early dyspnea relief between men and women hospitalized for acute heart failure: insights from the RELAX-AHF study. 
  • Site enrollment rate, outcomes, and study drug effects in a multicenter trial. Results from RELAX-AHF. 
  • Translational profiling of cardiomyocytes identifies an early Jak1/Stat3 injury response required for zebrafish heart regeneration. 
  • Use of High-Sensitivity Troponin T to Identify Patients With Acute Heart Failure at Lower Risk for Adverse Outcomes: An Exploratory Analysis From the RELAX-AHF Trial. 
  • Vasodilators in the treatment of acute heart failure: what we know, what we don't. 
  • Worsening Heart Failure Following Admission for Acute Heart Failure: A Pooled Analysis of the PROTECT and RELAX-AHF Studies.